This is a prospective study of expression profiling-based assessment of the efficacy of neoadjuvant therapy for rectal cancer.
Age ≥18 years, male or infertile female
Patients with rectal adenocarcinoma diagnosed by colonoscopic biopsy
Neoadjuvant therapy according to guideline recommendations
Endoscopic biopsy with access to biopsy tissue for subsequent RNA-seq testing
Samples are not collected, stored, or processed in accordance with specified requirements
Sample does not meet the requirements for subsequent RNA-seq testing
Cases enrolled with a subsequent diagnosis other than rectal adenocarcinoma.
The patient refuses or is unable to complete the entire neoadjuvant treatment
Rectal cancer patients intended for neoadjuvant therapy
Cohort
Prospective
Not listed
Objective Response Rate
The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST)
Overall survival
The time from the start of treatment to death due to any cause.
Progression free survival
The period from the date of beginning treatment until the date of disease progression or death from any cause
Total resection rate
Surgically removed tissue without residual cancer cells
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
